» Articles » PMID: 19857806

The Treatment of Liver Fibrosis Induced by Hepatocyte Growth Factor-directed, Ultrasound-targeted Microbubble Destruction in Rats

Overview
Journal Clin Imaging
Publisher Elsevier
Specialty Radiology
Date 2009 Oct 28
PMID 19857806
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purpose of this study was to explore the feasibility of using ultrasound-targeted microbubble destruction to treat liver fibrosis induced by hepatocyte growth factor (HGF).

Methods: Forty Wistar rats were divided into five groups after the models of liver fibrosis were prepared: (1) HGF, ultrasound, and microbubbles (HGF+US/MB); (2) HGF and ultrasound (HGF+US); (3) HGF and microbubbles (HGF+MB); (4) HGF (HGF); and (5) model alone (MA). All rats were killed after being transfected for 14 days. Recovery of the liver was detect by diffusion-weighted imaging (DWI) and pathological methods. Collagen I expression was detected by immunohistochemistry. Hepatocyte growth factor expression in the liver was detect by western blotting.

Results: The results of DWI and pathological examination showed the recovery of liver in HGF+US/MB group were better than those of other groups. In HGF+US/MB group, collagen I expression was less, and HGF protein was the highest among all the groups.

Conclusions: Ultrasound-targeted microbubble destruction could deliver HGF into the fibrotic liver and produce an antifibrosis effect, which could provide a novel strategy for gene therapy of liver fibrosis.

Citing Articles

The current progress and futural prospects of ultrasound-targeted microbubble destruction for liver diseases: a narrative review.

Yang B, Zhou H, Liu Y, Yang W, Li J, Zhou W Transl Gastroenterol Hepatol. 2025; 10:14.

PMID: 39944581 PMC: 11811551. DOI: 10.21037/tgh-24-53.


Ultrasonic particles: An approach for targeted gene delivery.

Walsh A, Gordon H, Peter K, Wang X Adv Drug Deliv Rev. 2021; 179:113998.

PMID: 34662671 PMC: 8518240. DOI: 10.1016/j.addr.2021.113998.


Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives.

Mahdinloo S, Kiaie S, Amiri A, Hemmati S, Valizadeh H, Zakeri-Milani P Acta Pharm Sin B. 2020; 10(7):1279-1293.

PMID: 32874828 PMC: 7451940. DOI: 10.1016/j.apsb.2020.03.007.


New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article.

Ebrahimi H, Naderian M, Sohrabpour A Middle East J Dig Dis. 2018; 10(3):133-148.

PMID: 30186577 PMC: 6119836. DOI: 10.15171/mejdd.2018.103.


Advances in ultrasound-targeted microbubble-mediated gene therapy for liver fibrosis.

Huang C, Zhang H, Bai R Acta Pharm Sin B. 2017; 7(4):447-452.

PMID: 28752029 PMC: 5518641. DOI: 10.1016/j.apsb.2017.02.004.